Heck Capital Advisors LLC Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Heck Capital Advisors LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,123 shares of the biotechnology company's stock, valued at approximately $225,000.

Several other large investors have also recently added to or reduced their stakes in ADMA. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of ADMA Biologics in the 4th quarter worth about $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the 4th quarter worth about $51,000. AlphaQuest LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $84,000. GF Fund Management CO. LTD. bought a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $85,000. Finally, CIBC Private Wealth Group LLC boosted its position in shares of ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after buying an additional 2,954 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ADMA shares. Raymond James raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Price Performance

ADMA stock traded up $0.26 during trading hours on Thursday, hitting $19.77. 2,356,143 shares of the stock traded hands, compared to its average volume of 3,691,637. The stock has a 50-day simple moving average of $20.67 and a 200 day simple moving average of $18.90. The company has a market cap of $4.72 billion, a P/E ratio of 70.61 and a beta of 0.57. ADMA Biologics, Inc. has a one year low of $9.35 and a one year high of $25.67. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the business posted $0.08 EPS. The business's revenue for the quarter was up 40.2% on a year-over-year basis. Equities analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total value of $158,069.28. Following the transaction, the director now owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. This trade represents a 6.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.